RT Journal Article
SR Electronic
T1 Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 665
OP 672
DO 10.2967/jnumed.124.267730
VO 66
IS 5
A1 Turco, Fabio
A1 Gillessen, Silke
A1 Herrmann, Ken
A1 Paone, Gaetano
A1 Omlin, Aurelius
YR 2025
UL http://jnm.snmjournals.org/content/66/5/665.abstract
AB The treatment landscape of prostate cancer is quite complex because of the many therapeutic options available in different disease settings (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, radiopharmaceutical therapy). Since in most cases we do not have comparative studies between these different agents, the best therapeutic sequence in patients with prostate cancer remains unsolved. In this review, we describe the different systemic therapeutic options available in each disease setting from localized disease to metastatic castration-resistant disease. We also indicate when to use each of these therapeutic options in the therapeutic sequence on the basis of the results of the available studies. A special focus of this review is the place of prostate-specific membrane antigen radiopharmaceutical therapy in the treatment algorithms.